Locally advanced rectal cancer with dMMR/MSI-H may be excused from surgery after neoadjuvant anti-PD-1 monotherapy: a multiple-center, cohort study

Locally advanced rectal cancer with dMMR/MSI-H may be excused from surgery after neoadjuvant anti-PD-1 monotherapy: a multiple-center, cohort study

ObjectiveExamine patients with locally advanced rectal cancer (LARC) with deficient mismatch repair (dMMR) or microsatellite instability-high (MSI-H) who received neoadjuvant immunotherapy (nIT), and compare the outcomes of those who chose a watch-and-wait (WW) approach after achieving clinical comp...

Full description

Bibliographic Details
Main Authors: Renfang Yang, Tao Wu, Jiehai Yu, Xinyi Cai, Guoyu Li, Xiangshu Li, Weixin Huang, Ya Zhang, Yuqin Wang, Xudong Yang, Yongping Ren, Ruixi Hu, Qing Feng, Peirong Ding, Xuan Zhang, Yunfeng Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-06-01
Series:Frontiers in Immunology
Subjects:
locally advanced rectal cancer
neoadjuvant immunotherapy
programmed cell death protein-1 inhibitor
mismatch repair-deficient
clinical complete response
watch-and-wait strategy
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1182299/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1182299/full

Similar Items